| | - Q4 2022 total revenues were $64.5 million
- Full year 2022 revenues were $254.4 million
- Vanda provides update on pipeline advancements and upcoming milestones
WASHINGTON, Feb. 8, 2023 /PRNewswire/ -- Vanda Pharmaceuticals, Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2022. “Our strong full year 2022 commercial performance positions Vanda well towards our objectives as we pursue a number of near term regulatory filings in bipolar I disorder, gastroparesis and insomnia,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board. “At the same time, we continue to believe in the strength of our intellectual property portfolio as we proceed with our appeal in the HETLIOZ patent litigation.” Financial Highlights Fourth Quarter of 2022 - Total net product sales from HETLIOZ® and Fanapt® were $64.5 million in the fourth quarter of 2022, a 5% decrease compared to $68.0 million in the fourth quarter of 2021.
- HETLIOZ® net product sales were $40.1 million in the fourth quarter of 2022, a 9% decrease compared to $44.1 million in the fourth quarter of 2021, due in part to continued reimbursement challenges for prescriptions for patients with Non-24-Hour Sleep-Wake Disorder (Non-24).
- Fanapt® net product sales were $24.4 million in the fourth quarter of 2022, a 2% increase compared to $24.0 million in the fourth quarter of 2021.
- Net income was $6.9 million in the fourth quarter of 2022 compared to $7.1 million in the fourth quarter of 2021.
- Cash, cash equivalents and marketable securities (Cash) was $466.9 million as of December 31, 2022, representing an increase to Cash of $12.1 million, or 3%, compared to September 30, 2022.
Full Year 2022 - Total net product sales from HETLIOZ® and Fanapt® were $254.4 million for the full year 2022, a 5% decrease compared to $268.7 million for the full year 2021.
- HETLIOZ® net product sales were $159.7 million for the full year 2022, an 8% decrease compared to $173.5 million for the full year 2021, due in part to continued reimbursement challenges for prescriptions for patients with Non-24.
- Fanapt® net product sales were $94.7 million for the full year 2022, essentially flat compared to $95.1 million for the full year 2021.
- Net income was $6.3 million for the full year 2022 compared to net income of $33.2 million for the full year 2021.
- Cash, cash equivalents and marketable securities (Cash) was $466.9 million as of December 31, 2022, representing an increase to Cash of $34.0 million, or 8%, compared to December 31, 2021.
Key Operational Highlights HETLIOZ® (tasimelteon) - Vanda is continuing to pursue regulatory approvals for HETLIOZ® in the indications of insomnia and jet lag disorder.
- In December 2022, the U.S. District Court for the District of Delaware delivered its decision for the consolidated HETLIOZ® patent lawsuit against defendants Teva Pharmaceuticals USA, Inc. (Teva) and Apotex Inc. and Apotex Corp. (Apotex), ruling in favor of the defendants. Vanda filed an appeal to the U.S. Court of Appeals for the Federal Circuit where an oral argument is scheduled for March 14, 2023. Despite the pending appeal, Teva has launched at risk its generic version of HETLIOZ® in the U.S.
- In December 2022, Vanda filed patent infringement lawsuits against each of Teva and Apotex in the U.S. District Court for the District of New Jersey asserting that Teva and Apotex’s generic versions of HETLIOZ® infringe U.S. Patent No. 11,285,129.
Tradipitant - Vanda is continuing to conduct an open-label safety study for tradipitant in gastroparesis and approximately the first 400 patients enrolled in the study were locked in preparation for the Company’s planned New Drug Application (NDA) submission. The study continues to enroll open label patients and Vanda continues to receive requests from patients seeking access to tradipitant through the Expanded Access program, which has multiple patients who have taken tradipitant for more than one year.
- Vanda is preparing for the submission of an NDA for tradipitant for patients with gastroparesis. Vanda expects to submit this NDA to the FDA in the first half of 2023.
- The Phase III study of tradipitant in the treatment of motion sickness is over 75% enrolled. Results are expected by mid-2023.
Fanapt® (iloperidone) - In December 2022, Vanda announced positive results in the Phase III clinical study of Fanapt® in acute manic and mixed episodes associated with bipolar I disorder in adults. Vanda plans to submit a supplemental New Drug Application (sNDA) in the first half of 2023.
Early-Stage Programs - In December 2022, Vanda announced results in a Phase II clinical study of VQW-765 in the treatment of acute performance anxiety in social situations. This is the first time that an alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist has shown efficacy in a clinical study of performance anxiety.
GAAP Financial Results Net income was $6.9 million in the fourth quarter of 2022 compared to net income of $7.1 million in the fourth quarter of 2021. Diluted net income per share was $0.12 in the fourth quarter of 2022 compared to diluted net income per share of $0.12 in the fourth quarter of 2021. Net income was $6.3 million for the full year 2022 compared to net income of $33.2 million for the full year 2021. Diluted net income per share was $0.11 for the full year 2022 compared to diluted net income per share of $0.58 for the full year 2021. 2023 Financial Guidance Given uncertainties surrounding the U.S. market for HETLIOZ® for the treatment of Non-24 as a result of the ongoing HETLIOZ® patent litigation, Vanda is unable to provide 2023 financial guidance at this time. Vanda will continue to evaluate its ability to provide financial guidance as the year progresses. Conference Call Vanda has scheduled a conference call for today, Wednesday, February 8, 2023, at 4:30 PM ET. During the call, Vanda’s management will discuss the fourth quarter and full year 2022 financial results and other corporate activities. Investors can call 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode number 4734670. A replay of the call will be available on Wednesday, February 8, 2023, beginning at 8:30 PM ET and will be accessible until Wednesday, February 15, 2023 at 8:30 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 4734670. The conference call will be broadcast simultaneously on Vanda’s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda’s website for a period of 30 days. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS Various statements in this press release, including, but not limited to, statements regarding Vanda’s plans for pursuit of regulatory approval of HETLIOZ® in the treatments of insomnia and jet lag disorder, tradipitant in the treatment of patients with gastroparesis and Fanapt® in the treatment of bipolar I in adults and the clinical development timeline for tradipitant in the treatment of motion sickness are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s ability to complete and submit the NDA for tradipitant and the sNDAs for HETLIOZ® and Fanapt® in the specified timeframes, the FDA’s assessment of the sufficiency of the data packages to be included in Vanda’s planned NDA submission for tradipitant and sNDA submissions for HETLIOZ® and Fanapt®, and Vanda’s ability to complete the Phase III clinical study of tradipitant in the treatment of motion sickness by mid-2023. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. | VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for share and per share amounts)
(unaudited) | | | | | Three Months Ended | | Twelve Months Ended | | | December 31
2022 | | December 31
2021 | | December 31
2022 | | December 31
2021 | | Revenues: | | | | | | | | | HETLIOZ® net product sales | $ 40,101 | | $ 44,069 | | $ 159,655 | | $ 173,536 | | Fanapt® net product sales | 24,381 | | 23,950 | | 94,727 | | 95,146 | | Total revenues | 64,482 | | 68,019 | | 254,382 | | 268,682 | | Operating expenses: | | | | | | | | | Cost of goods sold excluding amortization | 6,238 | | 6,236 | | 24,282 | | 25,629 | | Research and development | 18,454 | | 19,331 | | 85,770 | | 75,363 | | Selling, general and administrative | 32,782 | | 33,447 | | 136,485 | | 124,047 | | Intangible asset amortization | 379 | | 369 | | 1,516 | | 1,478 | | Total operating expenses | 57,853 | | 59,383 | | 248,053 | | 226,517 | | Income from operations | 6,629 | | 8,636 | | 6,329 | | 42,165 | | Other income (expense) | 2,984 | | (26) | | 4,971 | | 199 | | Income before income taxes | 9,613 | | 8,610 | | 11,300 | | 42,364 | | Provision for income taxes | 2,752 | | 1,532 | | 5,025 | | 9,212 | | Net income | $ 6,861 | | $ 7,078 | | $ 6,275 | | $ 33,152 | | Net income per share, basic | $ 0.12 | | $ 0.13 | | $ 0.11 | | $ 0.60 | | Net income per share, diluted | $ 0.12 | | $ 0.12 | | $ 0.11 | | $ 0.58 | | Weighted average shares outstanding, basic | 56,651,984 | | 55,787,252 | | 56,461,877 | | 55,548,122 | | Weighted average shares outstanding, diluted | 57,188,551 | | 57,229,805 | | 56,983,171 | | 56,921,836 | | VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited) | | | | | December 31
2022 | | December 31
2021 | | ASSETS | | | | | Current assets: | | | | | Cash and cash equivalents | $ 135,029 | | $ 52,071 | | Marketable securities | 331,830 | | 380,742 | | Accounts receivable, net | 33,512 | | 32,467 | | Inventory | 1,194 | | 1,025 | | Prepaid expenses and other current assets | 17,727 | | 11,996 | | Total current assets | 519,292 | | 478,301 | | Property and equipment, net | 2,573 | | 3,113 | | Operating lease right-of-use assets | 8,400 | | 9,272 | | Intangible assets, net | 18,565 | | 20,081 | | Deferred tax assets | 74,039 | | 74,878 | | Non-current inventory and other | 11,378 | | 8,147 | | Total assets | $ 634,247 | | $ 593,792 | | LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | Current liabilities: | | | | | Accounts payable and accrued liabilities | $ 45,551 | | $ 34,438 | | Product revenue allowances | 45,885 | | 39,981 | | Total current liabilities | 91,436 | | 74,419 | | Operating lease non-current liabilities | 8,813 | | 10,055 | | Other non-current liabilities | 6,800 | | 4,390 | | Total liabilities | 107,049 | | 88,864 | | Stockholders’ equity: | | | | | Common stock | 57 | | 56 | | Additional paid-in capital | 686,235 | | 669,223 | | Accumulated other comprehensive loss | (1,193) | | (175) | | Accumulated deficit | (157,901) | | (164,176) | | Total stockholders’ equity | 527,198 | | 504,928 | | Total liabilities and stockholders’ equity | $ 634,247 | | $ 593,792 | Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com  View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-301742439.html
SOURCE Vanda Pharmaceuticals Inc. | |
